中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
20期
118-120,123
,共4页
钱形邦%梁洪雁%梁肇和%侯浩联%侯秋华
錢形邦%樑洪雁%樑肇和%侯浩聯%侯鞦華
전형방%량홍안%량조화%후호련%후추화
重组人血管内皮抑制素%顺铂%博来霉素%恶性胸腔积液
重組人血管內皮抑製素%順鉑%博來黴素%噁性胸腔積液
중조인혈관내피억제소%순박%박래매소%악성흉강적액
Recombinant human endostatin%Cisplatin%Bleomycin%Malignant pleural effusion
目的：观察重组人血管内皮抑制素联合顺铂和博来霉素治疗肺癌恶性胸腔积液的近期效果及安全性。方法2011年10月~2013年10月，将73例肺癌伴恶性胸腔积液的患者经胸腔内置中心静脉导管排尽积液后随机分为A、B组。 A组37例给予胸腔内灌注重组人血管内皮抑制素30 mg+顺铂40 mg；B组36例给予胸腔内灌注重组人血管内皮抑制素30 mg+博来霉素粉针60 mg，两组均每周给药1次，连续给药3周。评价两组患者胸腔积液减少量的近期疗效、Karnofsky体力状况评分、不良反应发生率及生存率。结果胸腔积液减少量的近期疗效：A组的总有效率为72.97%，B组为88.89%，两组比较，差异无统计学意义(χ2=2.98，P>0.05)。A组的KPS体力状况评分改善率为37.84%，B组为61.11%，两组比较，差异有统计学意义(χ2=3.87，P<0.05)。两组的不良反应发生率均较低，差异无统计学意义(P>0.05)。两组的6个月生存率(A组为86.49豫，B组为94.44豫)差异无统计学意义(χ2=0.57，P>0.05)，1年生存率(A组为54.05豫，B组为77.78豫)差异有统计学意义(χ2=4.56，P<0.05)。结论重组人血管内皮抑制素联合顺铂和博来霉素治疗肺癌恶性胸腔积液均具有较好的效果，且不良反应少。
目的：觀察重組人血管內皮抑製素聯閤順鉑和博來黴素治療肺癌噁性胸腔積液的近期效果及安全性。方法2011年10月~2013年10月，將73例肺癌伴噁性胸腔積液的患者經胸腔內置中心靜脈導管排儘積液後隨機分為A、B組。 A組37例給予胸腔內灌註重組人血管內皮抑製素30 mg+順鉑40 mg；B組36例給予胸腔內灌註重組人血管內皮抑製素30 mg+博來黴素粉針60 mg，兩組均每週給藥1次，連續給藥3週。評價兩組患者胸腔積液減少量的近期療效、Karnofsky體力狀況評分、不良反應髮生率及生存率。結果胸腔積液減少量的近期療效：A組的總有效率為72.97%，B組為88.89%，兩組比較，差異無統計學意義(χ2=2.98，P>0.05)。A組的KPS體力狀況評分改善率為37.84%，B組為61.11%，兩組比較，差異有統計學意義(χ2=3.87，P<0.05)。兩組的不良反應髮生率均較低，差異無統計學意義(P>0.05)。兩組的6箇月生存率(A組為86.49豫，B組為94.44豫)差異無統計學意義(χ2=0.57，P>0.05)，1年生存率(A組為54.05豫，B組為77.78豫)差異有統計學意義(χ2=4.56，P<0.05)。結論重組人血管內皮抑製素聯閤順鉑和博來黴素治療肺癌噁性胸腔積液均具有較好的效果，且不良反應少。
목적：관찰중조인혈관내피억제소연합순박화박래매소치료폐암악성흉강적액적근기효과급안전성。방법2011년10월~2013년10월，장73례폐암반악성흉강적액적환자경흉강내치중심정맥도관배진적액후수궤분위A、B조。 A조37례급여흉강내관주중조인혈관내피억제소30 mg+순박40 mg；B조36례급여흉강내관주중조인혈관내피억제소30 mg+박래매소분침60 mg，량조균매주급약1차，련속급약3주。평개량조환자흉강적액감소량적근기료효、Karnofsky체력상황평분、불량반응발생솔급생존솔。결과흉강적액감소량적근기료효：A조적총유효솔위72.97%，B조위88.89%，량조비교，차이무통계학의의(χ2=2.98，P>0.05)。A조적KPS체력상황평분개선솔위37.84%，B조위61.11%，량조비교，차이유통계학의의(χ2=3.87，P<0.05)。량조적불량반응발생솔균교저，차이무통계학의의(P>0.05)。량조적6개월생존솔(A조위86.49예，B조위94.44예)차이무통계학의의(χ2=0.57，P>0.05)，1년생존솔(A조위54.05예，B조위77.78예)차이유통계학의의(χ2=4.56，P<0.05)。결론중조인혈관내피억제소연합순박화박래매소치료폐암악성흉강적액균구유교호적효과，차불량반응소。
Objective To observe the short-term curative effect and safety of recombinant human endostatin combined with cisplatin and bleomycin in the treatment of malignant pleural effusion induced by lung cancer. Methods From October 2010 to October 2013,73 patients with lung cancer complicated with malignant pleural effusion were randomly divided into group A and group B after complete discharge of effusion by implanting central venous catheter in thoracic cavity.37 patients in group A were given pleural infusion of 30 mg recombinant human endostatin+40 mg of cisplatin while 36 patients in group B were given pleural infusion of 30 mg of recombinant human endostatin+60 mg of bleomycin injection.The drug was administered once a week for continuous 3 weeks.Short-term curative effect of de-creased volume of pleural effusion,Karnofsky performance score,the incidence rate of adverse reaction and survival rate was assessed between two groups of patients. Results Short-term curative effect of decreased volume of pleural effu-sion:total effective rate in group A was 72.97%,while it was 88.89% in group B,and there was no statistical difference between two groups (χ2=2.98,P>0.05).The improvement rate of KPS physical condition score was 37.84% in group A, while it was 61.11%,in group B,and there was a statistical difference between two groups (χ2=3.87,P<0.05).Incidence rate of adverse reaction in both groups were lower,and there was no statistical difference between two groups (P>0.05). There was no statistical difference of 6-month survival rate (it was 86.49% in group A and 94.44% in group B) (χ2=0.57,P>0.05);there was a statistical difference of 1-year survival rate (it was 54.05% in group A and 77.78% in group B) (χ2=4.56,P<0.05). Conclusion Recombinant human endostatin combined with cisplatin and bleomycin in the treat-ment of malignant pleural effusion induced by lung cancer has better effect,and the adverse reaction is less.
